Whether the differences in opinion over the ‘performance-based standard’ that has risen as an issue during reimbursement discussions for the one-shot retinal dystrophy treatment ‘Luxturna’ will be reconciled is gaining attention.

Dailypharm found that the full-field sensitivity threshold (FST) has been set as the standard for evaluating the efficacy of Luxturna (voretigene neparvovec). This means that the FST result will become the standard that determines the reimbursement of Luxturna under the Risk Sharing Agreement (RSA) scheme.

However, it seems that a difference of opinion exists between the government and Novartis Korea over on what FST value should be accepted as an improvemen